Single inhaler therapy vs fixed dose ICS: Non‐fatal serious adverse events
Single inhaler therapy showed no clear difference in serious adverse events (non‐fatal) compared with fixed dose ICS (moderate certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Single inhaler therapy vs fixed dose ICS Serious adverse events (non‐fatal) · patients with asthma in adults not controlled on regular ICS Single inhaler therapy showed no clear difference in serious adverse events (non‐fatal) compared with fixed dose ICS (moderate certainty). Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice… (2013) · Cochrane Headline outcomes only | OR 0.97 [0.73, 1.29] | 3 studies · 4209 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid… 2013 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.